JCCC Seminar featuring Dr. Moshe Oren

Date: 
07/14/2011

Thursday, July 14, 2011
Time: Noon - 1PM
Room: 154 BSRB

Moshe Oren, PhD
Professor, Department of Molecular Biology
Weizmann Institute of Science
Rehovot, Israel

Talk Title "RNF20 and H2B Ubiquitylation: A New Link Between Histone Modifications and Cancer"

Co-sponsored by the JCCC

Light Lunch Served

www.cancer.ucla.edu

BSCRC and School of Engineering Chalk Talk featuring Dr. Luke Lee

Date: 
08/15/2011

Monday, August 15, 2011
12:00PM
483 Biomedical Sciences Research Building (BSRB)

Luke Lee, Ph.D.
Arnold and Barbara Silverman Distinguished Professor of Bioengineering
Director, Biomedical Institute for Global Healthcare Research & Technology
Co-Director, Berkeley Sensor & Actuator Center
University of California, Berkeley

Talk Title: Bionanoscience for Innovative Global Healthcare Research & Technology
(BIGHEART)

Lunch will be provided.

Stem Cell Club Meeting

Date: 
07/22/2011

We will be having a Stem Cell Club meeting this Friday,
July 22 at Noon in 154 BSRB

615 Charles E. Young Drive South

Our speaker will be Dr. Gustavo Miranda-Carboni who will be presenting work from his lab entitled "The role of WNT10B in a translational model for triple-negative breast cancer."

Lunch will be provided.

For more information please contact:
Rachel Kim RKim@mednet.ucla.edu

Stem Cell Club Meeting

Date: 
07/15/2011

We will be having a Stem Cell Club meeting this Friday,
July 15 at Noon in 154 BSRB

615 Charles E. Young Drive South

This week’s meeting will be an overview of the ISSCR meeting held last month.
We will have several speakers who attended the meeting give a brief presentation
on some aspect of the conference they would like to share with the group.

Lunch will be provided.

Stem Cell Club Meeting

Date: 
05/20/2011

We will be having a Stem Cell Club meeting this Friday,
May 20 at Noon in 154 BSRB

615 Charles E. Young Drive South

Our speakers will be Lydia Lee (Mikkola lab) and Ahmed Hegab (Gomperts lab) - “Stem cell population from murine tracheal submucosal gland ducts.”

Lunch will be provided.

For more information please contact:
Rachel Kim RKim@mednet.ucla.edu

World Stem Cell Summit

Date: 
10/05/2011

2011 WORLD STEM CELL SUMMIT

The UCLA Broad Stem Cell Research Center is a proud sponsor of the World Stem Cell Summit. The Summit is the largest interdisciplinary meeting of stem cell stakeholders, with an overarching purpose of fostering biomedical research and investment targeting cures.

Program and Registration Information: http://www.worldstemcellsummit.com/

World Stem Cell Summit

Date: 
10/04/2011

2011 WORLD STEM CELL SUMMIT

The UCLA Broad Stem Cell Research Center is a proud sponsor of the World Stem Cell Summit. The Summit is the largest interdisciplinary meeting of stem cell stakeholders, with an overarching purpose of fostering biomedical research and investment targeting cures.

Program and Registration Information: http://www.worldstemcellsummit.com/

World Stem Cell Summit

Date: 
10/03/2011

2011 WORLD STEM CELL SUMMIT

The UCLA Broad Stem Cell Research Center is a proud sponsor of the World Stem Cell Summit. The Summit is the largest interdisciplinary meeting of stem cell stakeholders, with an overarching purpose of fostering biomedical research and investment targeting cures.

UCLA scientists complete first genome mapping of molecule found in human embryonic stem cells that may regulate gene expression

Stem cell researchers at UCLA have generated the first genome-wide mapping of a DNA modification called 5-hydroxymethylcytosine (5hmC) in embryonic stem cells, and discovered that it is predominantly found in genes that are turned on, or active.       

The finding by researchers with the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA may prove to be important in controlling diseases like cancer, where the regulation of certain genes plays a role in disease development.

UCLA researchers begin first stem cell trials to treat eye diseases

Researchers at the Jules Stein Eye Institute (JSEI) have begun two clinical trials to determine the safety of stem cell therapy and patients’ ability to tolerate it for the treatment of two common, currently untreatable degenerative eye diseases. This FDA-approved study is only the second in the United States to use human embryonic-derived stem cells in patients and the first to address eye diseases.

Pages